Ready to start a conversation with this partner?
PGxOne™ Plus is a pharmacogenomics laboratory developed test (LDT) utilizing Next-Generation Sequencing (NGS) with turnaround time of 7-10 business days. Pharmacogenomics aims to predict how individual genetic variability impacts drug absorption, metabolism and activity. While one treatment approach may work well for one individual, the same approach may not be effective or may cause adverse drug effects/reactions in other patients. Results guide effective treatment decisions, potentially reducing adverse drug events (ADEs) and trial-and-error drug selection and dosing. Testing provides recommendations for over 300 commercial drugs, with extensive coverage of psychiatric, cardiac, pain medications, drugs to treat cancer (both supportive care and the tumor itself), and an additional 16 therapeutic areas. Utilizing cutting-edge NGS technology enables comprehensive coverage of ~200 genetic variants in >50 genes. Diagnostic test results are delivered to physicians and patients in a distilled and manageable report, giving them the relevant information to make more informed treatment decisions. Multiple report formats are available. The traditional PGxOne™ Plus test report has sections driven by a patient’s current medications and diagnosis codes. Drug interactions for current medications are also included (drug-to-drug, drug-to-food, drug-to-alcohol, and drug-to-lab). Other report formats designed for psychiatrists, cardiologists, and oncologists are available to provide options that might be more beneficial for those specialists. All report formats are comprehensive covering all 53 genes and 300+ drugs.